(Q44051703)

29 November 2017

The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring (English)

1 reference

29 November 2017

1 reference

Claudia R Felipe

1

1 reference

29 November 2017

Helio T Silva

2

1 reference

29 November 2017

Paula G P Machado

3

1 reference

29 November 2017

Riberto Garcia

4

1 reference

29 November 2017

Silvia R da Silva Moreira

5

1 reference

29 November 2017

José O M Pestana

6

1 reference

29 November 2017

1 August 2002

1 reference

29 November 2017

Clinical Transplantation

1 reference

29 November 2017

16

1 reference

29 November 2017

4

1 reference

29 November 2017

262-272

1 reference

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects

29 November 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Racial variation in dosage requirements of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Clinical Pharmacokinetics of Tacrolimus in Heart Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

Current opinions on therapeutic drug monitoring of immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Low systemic exposure to tacrolimus correlates with acute rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Dosing and management guidelines for tacrolimus in renal transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2002.01103.X

7 January 2021

10.1034/J.1399-0012.2002.01103.X

Identifiers

DOI

1 reference

29 November 2017

1 reference